174 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dart Neuroscience
Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dart Neuroscience
Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sterling Winthrop Pharmaceuticals Research Division
Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
R. W. Johnson Pharmaceutical Research Institute
Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
R. W. Johnson Pharmaceutical Research Institute
Cardiotonic agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3 (2H)-isoquinolinones and related compounds. Synthesis and activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Mitsui Toatsu Chemicals
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Cardiotonic agents. Synthesis and inotropic activity of a series of isoquinolin-3-ol derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ortho Pharmaceutical
Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Syntex Research
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Cardiotonic agents. 6. Synthesis and inotropic activity of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones: ring-contracted analogues of imazodan (CI-914).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert/Parke-Davis Pharmaceutical Research
Cardiotonic agents. 3. Synthesis and biological activity of novel 6-(substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Cardiotonic agents. 4. Synthesis and biological evaluation of N-substituted 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones: rigid structures derived from CI-930 and analogues.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institut De Recherche Jouveinal-Parke Davis
Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
RhôNe-Poulenc Rorer
Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hamdard University
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Navarra
Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astex Pharmaceuticals
Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sanofi Research Center
Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Washington University
Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Daqing Oil Field General Hospital
Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Washington University
Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Celgene
2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kaken Pharmaceutical
Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Csir-Indian Institute of Integrative Medicine
Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kyoto 607-8042
Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Janssen Pharmaceutica
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Horsham Research Center
Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kyorin Pharmaceutical
Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Janssen-Cilag
Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Amgen
Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kyorin Pharmaceutical
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Instituto De Qu£Mica M£Dica (Csic)
The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Islamic Azad University
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Matrix Laboratories
CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
St. John'S University
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Monash University (Parkville Campus)
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tanabe Seiyaku
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tanabe Seiyaku
Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Smithkline Beecham Pharmaceuticals
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tanabe Seiyaku
Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Pharma
Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kyorin Pharmaceutical
Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Biocrea
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Washington University
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Heriot-Watt University
Discovery of new inhibitor for PDE3 by virtual screening.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Korea Research Institute of Chemical Technology
Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Biotie Therapies
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
German University In Cairo
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
German University In Cairo
Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation
A new chemical tool for exploring the physiological function of the PDE2 isozyme.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sumitomo Pharmaceuticals
Occurrence, synthesis and biological activity of 2-(2-phenyethyl)chromones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Guizhou Medical University
Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ewha Womans University
Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hainan University
Novel Dihydrooxadiazinones as PDE3 Inhibitors for Treating Cancer.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Smith, Gambrell & Russell
Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
German University In Cairo
New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
The synthesis and biological evaluation of nucleobases/tetrazole hybrid compounds: A new class of phosphodiesterase type 3 (PDE3) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shiraz University
Advances in the Development of Phosphodiesterase-4 Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sichuan Academy of Medical Science & Sichuan Provincial People'S Hospital
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vertex Pharmaceuticals
8-Aryl xanthines potent inhibitors of phosphodiesterase 5.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Horsham Research Centre
Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against ![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Discovery and Optimization of ?-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Guangzhou University of Chinese Medicine
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tanabe Seiyaku
1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Schering-Plough Research Institute
Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Abbvie Deutschland
Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Rti International
Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Multi-target design strategies for the improved treatment of Alzheimer's disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Mitsubishi Tanabe Pharma
Structure Overhaul Affords a Potent Purine PI3K? Inhibitor with Improved Tolerability.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Amgen
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chiesi Farmaceutici
Phosphodiesterase inhibitors. Part 6: design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Kyorin Pharmaceutical
Synthesis and evaluation of novel 2-pyridone derivatives as inhibitors of phosphodiesterase3 (PDE3): a target for heart failure and platelet aggregation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Indian Institute of Chemical Technology
Optical resolution, absolute configuration, and activity of the enantiomers of proxyphylline.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vrije Universiteit
Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vrije Universiteit
Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vrije Universiteit
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
RhôNe-Poulenc Rorer
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hokuriku University
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Dipartimento Di Scienze Farmaceutiche, Firenze, Italy.
Novel and potent adenosine 3',5'-cyclic phosphate phosphodiesterase III inhibitors: thiazolo[4,5-b][1,6]naphthyridin-2-ones.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sterling Winthrop Pharmaceuticals Research Division
Novel cAMP PDE III inhibitors: imidazo[4,5-b]pyridin-2(3H)-ones and thiazolo[4,5-b]pyridin-2(3H)-ones and their analogs.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sterling Winthrop Pharmaceuticals Research Division
Cardiotonic agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds. Synthesis and inotropic activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
TBA
Inhibitors of phosphodiesterase as cancer therapeutics.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sichuan Academy of Medical Science & Sichuan Provincial People'S Hospital
Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sun Yat-Sen University
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Navarra
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activi![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Warner-Lambert
Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Pfizer
Synthesis and biological evaluation of 8-aryl-2-morpholino-7-O-substituted benzo[e][1,3]oxazin-4-ones against DNA-PK, PI3K, PDE3A enzymes and platelet aggregation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
La Trobe University
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Takeda Pharmaceutical
1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chiesi Farmaceutici
Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute